Abstract
Long-acting bronchodilators are the mainstay of pharmacological therapy for chronic obstructive pulmonary disease (COPD). This paper reviews the efficacy of the once-daily fixed-dose dual bronchodilator combination of indacaterol and glycopyrronium in COPD patients. Compared with single therapy with indacaterol, glycopyrronium and tiotropium and fixed combination salmeterol/fluticasone, fixed-dose indacaterol/glycopyrronium has clinically relevant effects on symptoms, health status, lung function, and rate of exacerbations and by that suggests a potential for dual bronchodilation as an important maintenance therapeutic option for some patients with COPD.
| Bidragets oversatte titel | The combination of indacaterol and glycopyrronium has effects on symptoms, lung function, and rate of exacerbations in COPD patients. |
|---|---|
| Originalsprog | Dansk |
| Tidsskrift | Ugeskrift for Laeger |
| Vol/bind | 176 |
| Udgave nummer | 38 |
| Sider (fra-til) | 2-6 |
| Antal sider | 5 |
| ISSN | 0041-5782 |
| Status | Udgivet - 15 sep. 2014 |